Jason Losee, DO
Family Medicine · Sioux City, IANPI 1053652883
Payments from drug & device makers
Across 125 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$425
- AstraZeneca$281
- Boehringer Ingelheim$248
- Merck$190
- Amgen$116
- Pfizer$105
- plus $449 from 16 others
What the payments were for
- Food & beverage$1,79399%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $425 |
| AstraZeneca | 14 | $281 |
| Boehringer Ingelheim | 18 | $248 |
| Merck | 12 | $190 |
| Amgen | 7 | $116 |
| Pfizer | 8 | $105 |
| Amarin Pharma, Inc. | 4 | $64 |
| Lilly USA, LLC | 4 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Johnson & Johnson | 2 | $32 |
| Eisai Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Mylan Specialty L.p. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $26 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,814 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 40 | $46,850 |
| EliquisApixaban | 63 | $32,135 |
| OzempicSemaglutide | 18 | $27,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $24,910 |
| FarxigaDapagliflozin Propanediol | 29 | $22,319 |
| MounjaroTirzepatide | 21 | $21,494 |
| EntrestoSacubitril/Valsartan | 16 | $15,897 |
| JardianceEmpagliflozin | 17 | $12,374 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,103 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,348 |
| JanuviaSitagliptin Phosphate | 13 | $7,325 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,573 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,178 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $3,796 |
| Pantoprazole Sodium | 129 | $3,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $58 | $68,34461 claims |
| PfizerEliquis | $105 | $32,13563 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $425 | $30,91732 claims |
| AstraZenecaFarxiga | $281 | $22,31929 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $248 | $17,94728 claims |
| NovartisEntresto | $14 | $15,89716 claims |
| MerckJanuvia | $190 | $7,32513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Sioux City
- Nicholas BechtoldSioux City$584K
- Frank MarinoSioux City$8K
- Paul PetersonSioux City$8K
- Jeffrey KrohnSioux City$7K
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.